HR Execs on the Move

CardioNet, Inc.

www.cardionet.com

 
CardioNet, Inc. (CardioNet), provides continuous, real-time ambulatory outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health.
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million
  • www.cardionet.com
  • 227 Washington St Ste 300
    Conshohocken, PA USA 19428-2086
  • Phone: 610.729.7000

Executives

Name Title Contact Details

Similar Companies

Valley Behavioral Health

Since 1987, Valley Behavioral Health has provided comprehensive treatment and services for people of all ages who are experiencing serious mental illness, substance use disorders and behavior problems. We believe people are best served in the least restrictive setting where care is tailored to the individual's needs. Families and community partners play an important role in a person's recovery.

Granville Health System

Granville Health System is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Oxford, NC. To find more information about Granville Health System, please visit www.granvillemedical.com

Eurogentec North America

Eurogentec North America is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chiltern

We are the leading, global mid-sized contract research organization. Our team of more than 4,200 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.